ReviewMetabolites2026
Tissue-Derived Small Extracellular Vesicles: Emerging Regulators of Inter-Organ Crosstalk in Health and Disease.
Review in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The recent progression of extracellular vesicles application in osteoporosis.Frontiers in pharmacology · 2026Review
- Proteoformics-driven new concept of human growth hormone in clinical endocrinology.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Small extracellular vesicles (sEVs; commonly referred to as "exosomes" in many studies) are nanoscopic messengers released by healthy and diseased cells that mediate intercellular communication by transferring proteins, lipids, and nucleic acids to local or distant recipient cells. In this narrative review, we synthesize recent evidence linking tissue-derived sEVs to neurological disorders (including neurodegeneration and traumatic brain injury), metabolic syndrome, cardiovascular diseases, cancers, and bone diseases, with a particular emphasis on CNS-periphery crosstalk across the blood-brain barrier. Compared with prior reviews that focus on single organ systems, we highlight cross-disease, cross-tissue mechanisms and summarize candidate biomarker cargos and therapeutic strategies in dedicated tables. While accumulating data support brain-body communication via sEVs, the concept of CNS-derived sEVs acting as a "third central efferent pathway" is presented here as an emerging hypothesis that complements-rather than replaces-neuronal and endocrine signaling. Overall, tissue-derived sEVs represent a promising but still evolving platform for diagnostic and therapeutic innovation, warranting standardized isolation/characterization and further clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.